Hemp, Law & Luxury: Beyond the Minibar — Article 3 of a Series
Cannabis Law Journal | Cannabis Law Report
Susan Burns, JD, LL.M. | S Burns Legal PLLC | LuxStateOfMind
November 12, 2026 is not an abstraction.
On that date, absent congressional action, Section 781 of P.L. 119-37 takes full effect — redefining hemp using a total THC threshold so restrictive that industry economists estimate it will eliminate 95% of the existing hemp-derived cannabinoid market.
The projected impact is substantial:
- A $28.8 billion industry
- 328,000 American jobs
- $1.5 billion in state tax revenue
- $79 billion in broader economic activity
These numbers have been cited repeatedly in the legislative debate. They are accurate. They are significant. And they are incomplete.
Largely absent from the discussion is the $14.3 billion U.S. luxury spa market, which has quietly, legally, and successfully integrated CBD wellness offerings into mainstream hospitality over the past five years.
Yet under the current compliance model, Washington risks treating a luxury resort offering a CBD massage enhancement as functionally equivalent to the unregulated sale of high-potency hemp intoxicants in convenience stores and gas stations.
Those are not the same regulatory problem. At present, federal policy discussions largely fail to distinguish between them.
I. What Already Exists: The Hospitality CBD Wellness Market
The luxury hospitality CBD wellness market is not speculative. It is an established and operational segment of the wellness economy, documented across a growing number of credentialed luxury properties across the United States and internationally.
Properties with Active CBD Spa Programs
Several high-end hospitality brands have integrated CBD into structured spa and wellness offerings:
- The St. Regis Aspen Resort offers CBD-enhanced treatments through its Remède Spa in partnership with Colorado hemp company That’s Natural!, including CBD oil, body lotion, and salves for spa use and retail purchase.
- The Ritz-Carlton, Amelia Island offers CBD-focused recovery treatments, soaks, and therapist-guided wellness services through its spa program.
- Salish Lodge & Spa features a dedicated Canna’Bliss spa menu that includes CBD massages, body treatments, and bath rituals.
- Grand Velas Riviera Maya introduced a CBD wellness experience in November 2021, featuring CBD-infused massage and facial treatments as part of its luxury spa programming.
These are not fringe-market operators. They are among the most credentialed properties in luxury hospitality — brands operating within highly compliance-sensitive environments where guest safety, reputational protection, and product consistency are central business concerns.
These operators evaluated the legal landscape, trained staff, developed protocols, and integrated CBD offerings into broader wellness programming under the structure established following the 2018 Farm Bill.
The Scale of the Existing Market
Approximately 13% of U.S. spas now offer CBD-infused treatments, while hotel and resort spas represent 30.3% of the U.S. spa services market.
The U.S. luxury spa market generated $14.3 billion in revenue in 2024 and is projected to reach $20.4 billion by 2030.
The luxury hospitality CBD segment is not synonymous with the broader hemp-derived cannabinoid market. It is, however, a documented and revenue-generating subset that developed within existing legal and commercial frameworks. Section 781 places this operating market segment at material risk.
A Critical and Underexamined Fact: Topicals Are Not Exempt
Public discussion surrounding Section 781 has focused primarily on intoxicating hemp beverages and edible products. Far less attention has been given to the statute’s application to topical formulations.
Section 781 applies the 0.4mg total THC threshold to hemp products intended for ingestion, inhalation, and topical use. This distinction is significant.
The U.S. Hemp Roundtable estimates that over 90% of current CBD products on the market exceed this threshold. That means the CBD massage oils, body lotions, and treatment formulations currently in use at luxury hotel spas across the country are not insulated from the November 12 deadline. They are subject to it.
Section 781 does not simply affect unregulated intoxicating products sold through convenience channels. It also reaches established wellness programs operating inside luxury hospitality environments that have, to date, functioned as lawful and professionally managed market participants. That distinction is receiving comparatively little attention in federal policy discussions.
II. The Legislative Landscape: Four Vehicles, One Deadline
Four legislative vehicles remain active in efforts to prevent, delay, or modify the November 12 implementation of Section 781. None offers a complete solution. Each reflects a different regulatory philosophy, political coalition, and level of practical viability.
What follows is a summary of the current federal landscape. For a more detailed practitioner analysis, see Four Bills, One Deadline, and an Industry on the Brink: A Practitioner’s Assessment of the Federal Hemp Legislative Landscape, published in the Cannabis Law Journal.
The Cannabinoid Safety and Regulation Act (Wyden–Merkley)
Introduced in December 2025 by Senators Ron Wyden and Jeff Merkley, the Cannabinoid Safety and Regulation Act (CSRA) would replace categorical prohibition with a federal regulatory approach. The bill establishes THC serving and container limits, FDA registration requirements, testing, packaging, and labeling standards, age restrictions, and prohibitions on synthetic cannabinoids.
Notably, it includes a topical-use category with thresholds that appear commercially workable for professional spa and wellness formulations. For luxury hospitality operators, the CSRA is currently the legislative vehicle most directly aligned with preserving regulated CBD wellness programming within a compliance-based structure.
The Hemp Safety Enforcement Act (Paul–Klobuchar)
Introduced on April 16, 2026, the Hemp Safety Enforcement Act would permit states to opt out of the federal restriction, preserving state-level hemp programs where authorized under local law. Senator Amy Klobuchar described a federal ban on hemp products as potentially devastating to existing markets.
The Hemp Planting Predictability Act
The Hemp Planting Predictability Act would delay implementation of Section 781 for two years, extending the effective date to November 12, 2028. Supported through bipartisan sponsorship in both chambers, the proposal reflects a narrower objective: to provide Congress additional time to develop comprehensive regulations rather than implementing immediate market-wide restrictions.
The Barr Framework Proposal
Representative Andy Barr has advanced an alternative that emphasizes age restrictions, marketing limitations, prohibitions on synthetic cannabinoids, and domestic sourcing requirements. Rather than categorical prohibition, the proposal reflects an effort to establish a structured regulatory model for hemp-derived cannabinoid products. A related Farm Bill amendment was withdrawn on April 22, 2026. Development of the standalone proposal continues.
The Farm Bill: April 30, 2026
On April 30, 2026, the House passed the Farm, Food, and National Security Act of 2026 by a vote of 224–200 without any delay or other impact on the hemp ban imposed by Section 781, which was enacted separately under P.L. 119-37. Both the Comer delay amendment and the Barr amendment were withdrawn prior to the vote. The legislation now proceeds to the Senate, where the ultimate outcome remains uncertain.
Where Things Stand
Since November 2025, the hemp industry has yet to secure a successful federal legislative reversal or modification of the pending restrictions. That record reflects the political difficulty of the issue, but not the inevitability of the outcome.
Effective advocacy at this stage depends less on broad industry rhetoric and more on precision: identifying distinct market segments, clarifying unintended consequences, distinguishing regulated wellness applications from unregulated intoxicant markets, and ensuring policymakers understand the full scope of what current language may affect — including sectors such as luxury hospitality wellness that have received comparatively little attention in the current debate.
III. The Argument Washington Hasn’t Heard
The hemp ban debate has been framed almost entirely around consumer products — gummies, beverages, vapes — and the manufacturers and retailers that sell them. In doing so, it has largely overlooked an entirely separate commercial category with a distinct operating structure, regulatory profile, and economic footprint: luxury hospitality wellness.
The luxury hospitality wellness market is structurally different from the consumer products market in ways that matter to regulators:
The luxury hospitality wellness market differs structurally from the broader consumer cannabinoid market in several ways that are directly relevant to regulators.
Adult-gated and operationally supervised. Access to luxury hotel spa environments is inherently restricted and staff-mediated. CBD treatments are delivered within structured service settings rather than through independent retail purchase channels. As a result, the child-access rationale frequently advanced in support of Section 781 is materially diminished within the hospitality spa model.
Staff-mediated service delivery. CBD spa treatments are administered by licensed therapists operating within defined treatment protocols. Guest intake, consultation, and supervision are built into the service environment. This is not an unmonitored retail transaction.
Documented product selection and compliance practices. Properties offering CBD wellness services have made deliberate operational decisions regarding sourcing, staff training, treatment protocols, and menu integration. These are structured cannabis wellness programs operating within luxury spa environments — not products sold through minimally supervised retail channels such as convenience stores or gas stations.
Insured and commercially accountable. Luxury hospitality operators function within extensive liability, insurance, and brand-protection frameworks. They possess substantial commercial incentives to avoid guest safety incidents and maintain documented risk-management practices.
Yet current federal policy discussions collapse materially different operating environments into a single regulatory category. A CBD massage delivered by a licensed therapist within a credentialed luxury resort is being evaluated alongside intoxicating synthetic cannabinoid products sold through minimally supervised retail channels. That equivalency is neither operationally precise nor proportionate from a regulatory standpoint. More importantly, the distinction — structural, documented, and legally relevant — remains absent from the current policy debate.
IV. What Proportionate Regulation Would Look Like
The luxury hospitality CBD wellness market does not need the regulatory vacuum created by the 2018 Farm Bill. It requires the kind of structure the industry has already begun building for itself: defined service models, documented standards, trained personnel, and defensible liability protocols.
A proportionate regulatory approach would include several core elements.
Defined service model. A CBD treatment administered by a licensed therapist within a licensed spa facility is not the same regulatory object as a hemp-derived gummy sold online without meaningful age verification. Federal policy should recognize the operational differences between supervised hospitality environments and general consumer retail distribution.
Clear product standards. Products should be lab-tested, accurately labeled, and traceable to compliant hemp sources. Existing standards infrastructure already provides a foundation for this approach. ASTM International’s D37 cannabis and hemp committee has published more than 50 standards addressing product quality, testing, and terminology. Yet no comparable model currently addresses hospitality-specific applications. That absence reflects a regulatory gap, not a lack of operational discipline within hospitality itself.
Staff training requirements. Not pharmaceutical-level, but practical standards that ensure staff can facilitate informed guest self-selection, recognize contraindications, and respond appropriately to guest concerns.
A liability safe harbor. A property that follows documented standards, uses tested products, employs trained staff, and maintains guest disclosure protocols should be protected from liability. A standard without insurer buy-in is a document. A standard with insurer buy-in is a safe harbor.
Elements of this approach are already emerging legislatively. The Wyden-Merkley CSRA moves toward differentiated regulatory treatment, including pathways relevant to topical formulations commonly used in professional spa settings. The Barr proposal reflects a similar structural orientation.
At the same time, industry observers anticipate increasing convergence among FDA, EFSA, and the UK FSA approaches to cannabinoid regulation over the next several years. That convergence creates an opportunity — not merely for domestic clarity, but for internationally harmonized standards applicable to luxury wellness hospitality markets globally. The luxury hospitality industry should be participating directly in that conversation.
V. The Window Is Open. It Will Not Stay Open.
The window for legislative action is narrowing. The practical consequences of Section 781 are no longer theoretical.
Washington cannot craft proportionate hemp policy for the luxury hospitality market without recognizing that the luxury hospitality market exists. The $14.3 billion U.S. luxury spa sector already operates documented, guest-approved CBD wellness programs at properties across the country. Yet that operating reality has barely entered the policy conversation.
The central issue is service model distinction. Luxury hospitality is structurally different from other hemp product channels. It is age-gated, staff-mediated, tested, and insured. A $342 CBD treatment delivered within a credentialed resort environment does not present the same regulatory profile as an intoxicating synthetic cannabinoid sold online to a minor. Treating both categories identically is not proportionate regulation.
Hospitality is uniquely positioned to make that case. The regulatory and legal infrastructure to support a differentiated structure already exists. What is missing is industry participation in the rooms where standards and policy are being written — in Congress, within regulatory agencies, and across standards-setting bodies currently operating without a hospitality voice at the table.
Federal action is coming regardless. The remaining question is whether luxury hospitality participates in shaping the outcome or is regulated without being meaningfully heard.
November 12 is not moving.
About the Author
Susan Burns, JD, LL.M. is the founding partner of S Burns Legal PLLC and the founder of LuxStateOfMind, a consulting practice helping luxury hospitality operators integrate cannabis wellness. She is Special Advisor to the Cannabis Trades Association (CTA), one of Europe’s leading cannabis trade bodies, and recognized among the Top 200 Cannabis Lawyers Globally. Susan chaired the ABA International Law Section’s inaugural Global Business of Cannabis Conference in Denver in 2021 — the first international legal conference on the global business of cannabis ever held. She is based between Cancún, Mexico and St. Paul, Minnesota, and is licensed to practice law in Minnesota and Arkansas.
This article is part of a series, Hemp, Law & Luxury: Beyond the Minibar, published in the Cannabis Law Report.
Legally Grounded. Globally Minded.
Selected Sources
P.L. 119-37, Section 781 — FY2026 Agriculture Appropriations Act, signed November 12, 2025.
Whitney Economics / US Hemp Roundtable. Cited for $28.8 billion market size, 328,000 jobs, $1.5 billion state tax revenue, $79 billion broader economic impact.
Grand View Research, U.S. Luxury Spa Market Size & Outlook to 2030, January 2025. Cited for $14.3 billion US luxury spa market revenue (2024) and $20.4 billion projection (2030).
Global Market Insights, Spa Market Size, 2025. Cited for hotel/resort spa share (30.3%) and $27.8 billion global hotel/resort spa revenue.
Media.Market.us, Spa Industry Statistics and Facts, January 2026. Cited for 13% of US spas offering CBD-infused treatments.
Frier Levitt, ‘The Redefinition of Hemp Under Federal Law,’ March 2026. Cited for legislative analysis and industry impact assessment.
Cannabis Business Times, ‘Bipartisan Bill Aims to Delay Federal Hemp Product Ban Until November 2028,’ January 2026. Cited for legislative vehicle summaries.
Wyden.senate.gov, ‘Wyden Reintroduces Bill to Keep Hemp on the Market with Strong Consumer Protections,’ December 2025. Cited for CSRA provisions.
St. Regis Aspen Resort, Remède Spa CBD program. Grand Velas Riviera Maya, CBD Experience (launched November 2021). Ritz-Carlton Amelia Island, CBD spa treatments. Salish Lodge & Spa, Canna’Bliss menu. All verified from property spa menus and press materials.
Susan Burns, JD, LL.M., ‘Four Bills, One Deadline, and an Industry on the Brink: A Practitioner’s Assessment of the Federal Hemp Legislative Landscape,’ Cannabis Law Journal, 2026.